Radioiodine is an effective, inexpensive, and safe treatment for Graves' hyperthyroidism, but its immunological effects must be taken into account

Journal of Endocrinological Investigation

Volumn 22, Issue 4, 1999, Pages 310-312

  Chiovato, L ^a   Rocchi, R ^a   Fiore, E ^b  

^a UNIVERSITY OF PISA   (Italy)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

131I therapy; Graves' disease; Thyroid associated ophthalmopathy; Thyroid stimulating antibody; Thyroid ultrasound volume; TSH blocking antibody

Indexed keywords

ANTIGEN; RADIOACTIVE IODINE;

CONTROLLED STUDY; EYE DISEASE; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; SHORT SURVEY;

EID: 0032902057     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03343562     Document Type: Short Survey

References (11)

1. Chiovato L., Santini F., Pinchera A. Treatment of hyperthyroidism. Thyroid International 1995, 3: 2-22.
2. Franklyn J.A. The management of hyperthyroidism. N. Engl. J. Med. 1994, 330: 1731-8.
3. Williams E.D. Biological effects of radiation on the thyroid. In Braverman L.E., Utiger R.D., Ed. Werner and Ingbar's the Thyroid, sixth edition. Philadelphia, Lippincott Co. 1991, p. 421-36.
4. Heufelder A.E. Retro-orbital autoimmunity. Baillieres Clin. Endocrinol. Metabol. 1997, 11: 499-520.
5. Feliciello A., Porcellini A., Ciullo I., Bonavolontà G., Avvedimento E.V., Fenzi G.F. Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue. Lancet 1993, 342: 337-438.
6. Kubota S., Gunji K., Ackrell B., Cochran B., Stolarski C., Wengrowicz S., Kennerdell J., Hiromatsu Y., Wall J. The 64-kilodalton eye muscle protein is the flavo-protein subunit of mitochondrial succinate dehydrogenase: the corresponding serum antibodies are good markers of an immune-mediated damage to eye muscle in patients with Graves' hyperthyroidism. J. Clin. Endocrinol. Metab. 1998, 83: 443-447.
7. Chiovato L., Fiore E., Vitti P., Rocchi R., Rago T., Dokic D., Latrofa F., Mammoli C., Lippi F., Ceccarelli C., Pinchera A. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J. Clin. Endocrinol. Metab. 1998, 83: 40-46.
8. Pinchera A., Liberti P., Martino E., Fenzi G.F., Grasso L., Rovis L., Baschieri L. Effects of antithyroid therapy on the long-acting thyroid stimulator and the antithyroglobulin antibodies. J. Clin. Endocrinol. Metab. 1969, 29: 231-238.
9. DeGroot L.J. Radioiodine and the immune system. Thyroid 1997, 7: 259-264.
10. Chiovato L., Santini F., Vitti P., Bendinelli G., Pinchera A. Appearance of thyroid stimulating antibody and Graves' disease after radioiodine therapy for toxic nodular goitre. Clin. Endocrinol. (Oxf.) 1994, 40: 803-806.
11. Bartalena L., Marcocci C., Bogazzi F., Manetti L., Tanda M.L., Dell'Unto E., Bruno-Bossio G., Nardi M., Bartolomei M.P., Lepri A., Rossi G., Martino E., Pinchera A. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N. Engl. J. Med. 1998, 338: 73-78.